Cutaneous and leptomeningeal vascular malformations are hallmarks of the Sturge-Weber Syndrome (SWS), resulting in chronic ischemic tissue damage. The mechanisms underlying the pathobiology of these progressive lesions are unknown. Aberrant expression of angiogenic factors has been implicated in the genesis and maintenance of vascular malformations. To assess the role of angiogenesis in SWS vascular lesions we determined the expression of key angiogenic factors by immunohistochemistry and in situ hybridization in 8 SWS patients (age: 8 months to 18 years). We observed increased expression of vascular endothelial growth factor (VEGF), its cognate receptors VEGFR-1, VEGFR-2, and neuropilin (NP)-1 as well as Tie2 in leptomeningeal SWS blood vessels. Intriguingly, these factors are known to be transcriptionally induced by hypoxia-inducible factor (HIF). The HIF system has emerged as the key regulatory system of responses to hypoxia. Immunohistochemical analysis demonstrated markedly elevated nuclear HIF-1> and HIF-2> protein levels in SWS vessels. Concomitantly, SWS vessels revealed signs of enhanced endothelial cell (EC) turnover as evidenced by increased EC proliferation and apoptosis. Thus, in terms of angiogenesis, vascular malformations in SWS are not static lesions but constitute dynamic structures. Our observation of a dysregulated HIF-> expression in SWS vessels are in agreement with recent findings that EC-specific HIF activation provides a setting which supports and sustains angiogenesis and could be of potential use for developing therapeutic strategies to treat these currently incurable lesions.
INTRODUCTION
Sturge-Weber Syndrome (SWS), also termed encephalotrigeminal angiomatosis, is a rare congenital, non-inherited neurocutaneous disorder affecting the cephalic venous vasculature (1) . SWS classically presents with a facial capillary vascular malformation (port wine stain) in the distribution of the trigeminal nerve in association with an ipsilateral vascular malformation of the leptomeninges, that is, leptomeningeal angioma (LA), most often overlying the parietal and occipital cortex. Seizures, glaucoma, migraine, strokelike episodes, hemiparesis, and mental retardation are among the wide array of clinical features that are typically progressive in nature. The localized vascular abnormalities in SWS patients that affect the face, eye, and brain have been hypothesized to arise from a developmental failure of the cephalic venous plexus to regress and properly mature. Somatic mutations have been cited as a mechanism for the pathogenesis of SWS (2) . However, only a few studies have analyzed the basic biology of these lesions and the putative genetic aberration is still unknown.
Leptomeningeal angiomas are composed of tortuous, thin-walled venous structures of variable size within the thickened leptomeninges. The underlying cortex is typically atrophic, displaying neuron loss, astrogliosis and calcifications. It is hypothesized that the chronic tissue damage in SWS patients results from impaired superficial cortical venous drainage, leading to microcirculatory stasis that promotes chronic ischemia of the cortex and underlying white matter (3) . Cortical hypoxia is associated with various pathophysiological changes seen in SWS patients such as blood-brain barrier disruption, increased capillary permeability, and altered local tissue metabolism (4, 5) . Thus, O 2 gradients may be crucial in driving the progression of the disease, which is primarily a disorder of vascular development. It is currently unknown whether angiogenesis occurs in LA and to what degree it contributes to the genesis and/or maintenance of these lesions.
Experimental models and studies on stroke patients have shown that hypoxia/ischemia is a strong inducer of vascular proliferation. Hypoxia/ischemia-induced angiogenesis is a multi-step process by which new blood vessels are formed by sprouting from pre-existing ones. Gene deletion studies have identified at least two sets of endothelial cell (EC)-specific transmembrane tyrosine kinase receptors (TKR) and their ligands that are essential for normal vascular development. These include receptors for vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and the co-receptor neuropilin (NP)-1, as well as the TKR Tie1 and Tie2 with the Tie2-specific ligands angiopoietin (Ang)-1 and Ang-2 (6) . Phenotypes of null mutant mice indicate that the sequential expression of these specific growth factors and their receptors determine survival, proliferation, differentiation, and morphogenesis of endothelia in vivo. VEGF-and VEGFRY2-deficient mice fail to develop a vasculature and have few ECs (7Y9). Indeed, VEGFR-2 appears to be the major signal transducer for VEGF in ECs. NP-1-null mutant mice die at embryonic day 13.5 with impaired vascularization of the central nervous system (10) . NP-1 promotes angiogenesis by acting as a coreceptor for VEGFR-2, thereby enhancing the binding capacity of VEGF to this receptor (11) . Targeted inactivation of Tie1 or Tie2 does not interfere with normal development of a primary vasculature, but subsequent steps of vascular remodeling are not induced (12) . Hence it was postulated that angiopoietins and the tie-family exert their function at later stages of vascular development than VEGF, that is, vascular sprouting and remodeling.
A mounting body of evidence suggests that hypoxia is a major trigger for both physiological and pathological angiogenesis. The hypoxia-inducible factor (HIF) system has emerged as the key regulatory system of responses to hypoxia (13, 14) . The HIF transcriptional complex is a heterodimer composed of HIF-> and HIF-A subunits belonging to the basic helix loop helix-PAS family of transcription factors. Whereas HIF-A subunits are constitutively expressed, specificity to hypoxia-mediated responses is conferred by HIF-> subunits, namely HIF-1> and HIF-2>. Transcriptional activity of HIF-> subunits by cellular O 2 is mainly regulated by protein levels and transactivation domain function. Under normoxic conditions HIF-> is subject to rapid ubiquitination and proteasomal degradation requiring binding of von-Hippel-Lindau protein (pVHL) to specific hydroxylated prolyl residues within the HIF-> subunits. Prolyl hydroxylation is mediated by a subfamily of 2-oxoglutarate dependent dioxygenases termed HIF prolyl-hydroxylase (PHD). Following decreases in oxygen levels HIF-> subunits are stabilized and rapidly accumulate. The importance of HIF in blood vessel growth was confirmed in a number of gene knockout studies demonstrating impaired vascularization in HIF-1> (15, 16) and HIF-1A-deficient mice (17) reminiscent of the VEGF-KO phenotype (7, 8) . Recent studies suggest that HIF/hypoxia may operate as an intrinsic regulator of EC growth and function by stimulating receptor and ligand expression. Thus, HIF-> subunits have been reported to induce VEGFR-1, VEGFR-2, and Tie2 (18Y21). HIF-2>, but not HIF-1> has been shown to transactivate promotor sequences of the two TKR Tie2 and VEGFR-2, mainly expressed in EC (19, 21) .
Aberrant expression of angiogenic factors has been implicated in the genesis and maintenance of vascular malformations (22) . The molecular biology of vascular malformations in SWS, including the role of angiogenic growth factors in their pathobiology and maintenance, has so far not been explored. The purpose of this study was to characterize the expression of key players of angiogenesis in the pathobiology of LA in SWS patients using nonradioactive in situ hybridization and immunohistochemistry techniques.
MATERIALS AND METHODS

Human Tissue Specimens
Samples were taken from SWS-patients undergoing partial or total hemispherectomies for epilepsy treatment. A total of 8 SWS samples were analyzed, all of them featuring LAs composed of at least 3 layers of vessels. Resected epilepsy foci obtained from 5 non-SWS patients suffering from intractable seizures served as negative controls as previously described (23) . Conditions of surgery and sampling procedures were similar to that of SWS patients. Clinical information on SWS and control patients is summarized in the Table. After resection of respective brain tissues, samples were immediately placed in fixative medium and embedded in paraffin. Four-Km-thick sections were cut, mounted on SuperFrost microscope slides (MenzelGläser, Braunschweig, Germany), dried for 45 minutes at 70-C, and incubated for 24 hours at 37-C. Sections were stained with hematoxylin and eosin and with Elastica van Gieson for routine diagnosis. A neuropathologist confirmed SWS and normal brain histology according to conventional criteria.
Immunohistochemistry
Immunohistochemical experiments were carried out essentially as previously described (24) . Human glioblastoma multiforme sections were used to establish antibody concentration and served as positive staining controls. The following antibodies were used: rabbit anti-human polyclonal The following secondary antibodies were used according to the primary antibody: biotinylated goat anti-rabbit (1.2 mg/ml), rat anti-mouse (1.9 mg/ml) (both from Dianova, Hamburg, Germany), rabbit anti-mouse (0.6 mg/ml; Dako). Secondary antibodies were diluted 1:200 in 10% natural goat serum (NGS)/PBS/0.01% Triton X (Sigma, Steinheim, Germany). After incubation for 1 hour at room temperature, slides were washed 3 times for 5 minutes in PBS, incubated for 30 minutes with peroxidase conjugated streptavidin (Vectastain Kit ABC, Vector Laboratories, Inc., Burlingame, CA), and then rinsed 4 times in PBS. For signal amplification, sections stained for VEGFR-2 were additionally treated with a second secondary antibody (i.e. goat anti-rabbit, Dianova) and sections stained for monoclonal anti-Hif-1> were additionally treated with the Tyramide Amplification System (NEL-700 Kit, Perkin Elmer, Boston, MA), following the manufacturer_s instructions, with 1:100 dilution. Color reaction was performed with 3-amino-9-ethylcarbazole, 0.006% H 2 O 2 (AEC, Vector Laboratories). Color reaction was stopped by washing sections in PBS. Using neuronal staining intensity of the underlying cortex as an internal control, an objective control for equal staining results was given. Sections were briefly counterstained in hematoxylin, rinsed in aqua dest, and mounted in Elvanol.
Double-Labeling Experiments Double Immunohistochemistry Labeling
To analyze EC proliferation, sections were double labeled with anti-Ki67 (staining of proliferating cells) and anti-CD34 (staining of ECs) as described above. For visualization of Ki-67 staining, color reaction was performed with 5-Bromo-4-chloro-3-indolyl-phosphate (BCIP)/4-Nitro blue tetrazolium chloride (NBT) (Roche Diagnostics, Mannheim, Germany) after incubation with an alkaline phosphatase conjugated streptavidin ABC-Kit diluted in levamisole (DAKO, Carpinteria, CA). Washing steps were performed with TBS. To block primary antibody binding sites sections were incubated with the double staining enhancer (DS kit; Zymed, South San Francisco, CA) before continuing with the second primary antibody.
Double Immunofluorescence Labeling
To show colocalization of HIF-1> and HIF-2> with ECs, immunofluorescence was performed using standard protocol and primary antibodies as described above. The following fluorescent secondary antibodies were used according to primary antibody: goat anti-rabbit Alexa Fluori488 (2 mg/ml), goat anti-mouse Alexa Fluori568 (2 mg/ml; Molecular Probes, Göttingen, Germany), Extravidin 488 (1.5Y3 mg/ml; Sigma, St. Louis, MO. Antibodies were diluted 1:200 in 10% NGS/PBS/0.01% Triton or 10% NGS/ TBS/0.01% Triton respectively. Omission of the first antibody served as a negative control. Cell nuclei were briefly counterstained with 4_,6-diamidino-2-phenyindole, dilactate (Sigma), diluted 1:1000 in PBS. Evaluation of double staining was performed using a fluorescence microscope.
EC Apoptosis
To detect apoptotic/necrotic ECs, we used the dUTP nick-end labeling assay (TUNEL assay) (ApopTag plus, Intergen, Heidelberg, Germany), according to the manufacturer_s instructions. Following the color reaction with BCIP/NBT, ECs were labeled using an anti-CD34 antibody. Sections were briefly counterstained with hematoxylin and mounted in Elvanol. In two cases, it was not possible to obtain specific TUNEL staining. Accordingly, TUNEL staining was assessed in the remaining six samples only.
In Situ Hybridization
In situ hybridization was carried out essentially as previously described (24) . Slides were incubated in 0.2 M HCL for 10 minutes at room temperature followed by digestion with proteinase K (10 Kg/ml) (Sigma, Germany) for 10 minutes at room temperature and acetylation with 0.1 M triethanolamine (Sigma, Germany) mixed with 0.25% acetic anhydride (Fluka, Deisenhofen, Germany) for 10 minutes at room temperature. Sections were then prehybridized in 4Â SSC, 0.02% SDS, 5Â Denhardt_s solution, 50% ultrapure formamide (Gibco BRL, Karlsruhe, Germany), 5% dextran sulfate (Sigma, Germany) and 0.5 mg/ml yeast tRNA (Sigma, Germany) for 5 hours at room temperature. Hybridization was carried out with a digoxigenin labeled (Boehringer, Mannheim, Germany) cRNA generated by in vitro transcription using a VEGF cDNA templates (25) . Labeled cRNA probes were used at a concentration 0.5 ng RNA/Kl. Hybridization with sense probes served as control and gave no specific signals (data not shown). Tissue sections were incubated in a humidified chamber under glass coverslips at 70-C (Hybridisierungsofen, Biometra, Goettingen, Germany) for 16 to 18 hours. Posthybridization stringency washes included 2Â SSC for 30 minutes at 70-C, 2Â SSC for 2 minutes at room temperature, 0.2Â SSC for 10 minutes at 70-C and 2Â SSC for 5 minutes at room temperature. Each wash was carried out twice. Hybridized probes were detected by an anti-digoxigenin antibody conjugated to alkaline phosphatase (diluted 1:500, 1 hour at room temperature) using nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate solution as substrate (Boehringer). Sections were rinsed in PBS, counterstained with hematoxylin, and mounted in Elvanol.
Morphometry and Data Analysis
For semiquantitative analysis, two independent observers, blinded to all clinical information of the specimens, assessed and quantified EC staining intensity and quantity in four randomly chosen magnification fields (200Â) in SWS and control tissue specimens. Staining intensity in SWS specimens was recorded as equal (0), mildly (1), moderately (2) , and strongly (3) higher than staining intensity of subarachnoid vessels in control specimens. Because the expression of factors was found to be inhomogeneously distributed throughout the leptomeningeal lesion, the pattern and distribution of expression of the various antigens in SWS specimens was assessed and number of stained vessels counted and documented as 0 to 30% (I), 30% to 60% (II), and 60% to 100% (III) stained SWS-vessels. The staining intensity and quantity parameters were united to a score by multiplication. Box and Whisker plots for each antigen were created using SPSS statistic software, version 11.0 for Windows. Gliosis was quantified by counting the number of GFAP expressing astrocytes in 5 randomly chosen, high magnification fields (400Â). For quantification of EC proliferation and apoptosis, the percentage of CD34 expressing ECs colocalizing with Ki67 or TUNEL, respectively, was determined. For each specimen, 10 randomly chosen magnification fields (200Â) in the subarachnoid space and in the cortical brain parenchyma, respectively, were evaluated. Results are represented as mean T SEM. Statistical comparisons of values were made using the non-parametric Mann-Whitney U test. Statistical significance was assumed at p G 0.05.
RESULTS
In all SWS specimens we observed an abundance of abnormal vessels in the subarachnoid space, the pathological hallmark of the leptomeningeal manifestation of SWS. The majority of vessels were thin-walled and of variable calibers with some being markedly ectatic and distorted (Fig. 1) . ECs within the LA stained positive for CD34 and were covered by a smooth muscle cell/pericyte layer as evidenced by the expression of smooth muscle actin. To further characterize the venous or arterial nature of SWS vascular malformations, the existence of an internal elastic lamina was assessed using the Elastica van Gieson stain. As shown in Figure 1 , most SWS vessels did not show an internal elastic lamina, indicating that LA primarily consists of vessels with venous characteristics. Single arterial vessels with an internal elastic lamina were scattered within the leptoangiomatous lesion. Histological analysis of the underlying cortex revealed the typical hexalaminar organization of the neocortex. In 7 out of 8 SWS cases, varying degrees of focal calcifications could be observed in the cortex, mostly located superficially in the stratum moleculare, but in some cases also scattered throughout all neuronal layers and occasionally in the adjacent white matter. As further evidence of chronic damage, SWS brain samples revealed a focal reduction of neurons with a concomitant gliosis. Immunohistochemical staining for GFAP confirmed a marked gliosis in SWS samples with numerous reactive astrocytes and significant increases in total astrocytic cell number (33.6 T 5.4; p G 0.05) as compared to control specimens (16.2 T 1.2).
Expression of VEGF, VEGFR-1, VEGR-2, and Neuropilin-1
The VEGF/VEGFR-system has previously been implicated in the development and propagation of blood vessel malformations. For this reason, expression of the ligand VEGF and the VEGF binding receptors VEGFR-1, VEGFR-2 and NP-1 was analyzed by immunohistochemistry in 8 cases of SWS. Representative sections are depicted in Figure 2A . For semiquantitative analysis, staining intensity as well as pattern and distribution of expression was assessed in comparison to control specimens. Both parameters were unified by multiplication to a score shown in Figure 2B . Seven out of eight SWS cases demonstrated increased VEGF protein staining of ECs in subarachnoid vessels with a median score of 4 (p G 0.05). Blood vessels within the underlying cortex similarly revealed increased staining patterns. Control specimens only demonstrated a faint VEGF staining of ECs.
As VEGF is a secreted protein, positive immunostaining cannot distinguish whether the protein is expressed in the cell or bound to the surface of cell. For this reason, in situ hybridization experiments were performed to localize VEGF mRNA expression. SWS vessels did not demonstrate elevated VEGF mRNA signals as compared to control specimens. However, throughout the underlying cortex increased VEGF mRNA expression was noted in neurons and glial cells of SWS patients (Fig. 2C) . Statistically significantly enhanced expression of VEGFR-1 and VEGR-2 was seen in SWS vessels in 5 of 8 SWS cases with a median score of 3 (p G 0.05) and 2 (p G 0.05), respectively ( Fig. 2A,  B) . Subarachnoidal blood vessels in control specimens expressed only low levels of VEGFR-1, VEGFR-2, and NP-1. In contrast, NP-1 staining was elevated in 7 of 8 SWS cases with a median score of 5 (p G 0.05). Interestingly, neither expression of VEGFR-1, VEGFR-2, nor of NP-1 was increased in intracortical vessels of SWS patients.
Expression of Tie2
The angiopoietin/Tie2 system is another crucial factor governing angiogenesis and has been described to play a functional role in vascular malformations. Expression of the angiopoietin receptor Tie2, as assessed by immunohistochemistry, was not detected in subarachnoidal and intracortical vessels of control specimens. However, Tie2 expression was elevated in SWS LA vessels in all cases with a median score of 3 (p G 0.05) ( Fig. 2A, B) , while expression in intracortical vessels was not observed.
Expression of HIF-1> and HIF-2>
Given the increasing evidence that HIF-1> and HIF-2> may act as transcriptional master switches of EC function with decisive roles in physiological and pathological angiogenesis, we were interested to further analyze their involvement in pathological blood vessel growth in SWS. Immunohistochemical analysis revealed elevated HIF-1> and HIF-2> protein levels in ECs of SWS leptomeningeal blood vessels in all 8 patients with a median score of 4 (p G 0.05) and 7.5 (p G 0.05), respectively, as compared with normal intraparenchymal blood vessels from the same patient or with leptomeningeal/intraparenchymal vessels in control brains (Fig. 3A) . Increased HIF-1> and HIF-2> protein levels were found in the cell nucleus and to a lesser degree also in the cytoplasm of ECs. To further validate EC-specific expression we performed double immunofluorescence analysis. As demonstrated in Figure  3B , HIF-1> and HIF-2> protein was found to be coexpressed with the EC marker CD34 identifying HIF expressing cells as ECs.
Vascular Remodeling, Endothelial Cell Apoptosis, and Proliferation
Both increased expression of angiogenic factors such as the VEGF/VEGFR and the angiopoietin/Tie2 system as well as activation of key transcriptional regulators of angiogenesis, such as HIF-1> and HIF-2>, are observed in settings of ongoing angiogenesis. Thus, SWS vessels may undergo active reorganization rather than remaining static lesions. To assess the dynamics of blood vessel maintenance in SWS, we performed double-label immunohistochemistry to assess vessel proliferation and vessel regression (Fig. 4) . EC proliferation was determined by quantifying co-labeling of Ki67 and CD34. As compared to control tissues (0.0 T 0.0), EC proliferation in SWS vessels in the subarachnoid space was clearly increased (0.25% T 0.07%; p G 0.05). Intracortical blood vessels of SWS patients showed a slightly elevated EC proliferation rate (0.08% T 0.07%; p = 0.24) as compared to controls (0.0 T 0.0) but without reaching statistical significance. Infrequently, single Ki67 expressing (proliferating) cells were detected in the subendothelial cell layer that did not co-stain with CD34. Apoptotic ECs were detected by double labeling experiments combining the TUNEL assay with CD34 immunohistochemistry. EC apoptosis in SWS vessels in the subarachnoid space was increased (0.15% T 0.05%; p G 0.05) as compared to controls (0.0 T 0.0). EC apoptosis could not be observed in the intracortical vessels of either SWS patients or controls.
DISCUSSION
The importance of angiogenesis in driving and maintaining different types of vascular malformations has been underlined by a number of studies (22) . Due to the progressive nature of SWS lesions (3), we reasoned by analogy to other vascular malformations that SWS is also an angiogenic lesion. This prompted us to analyze some of the key angiogenic molecules to further characterize potential factors functionally implicated in the pathogenesis of vascular SWS lesions.
SWS As an Angiogenic Lesion
VEGF and its receptor VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR) are major regulators of vasculogenesis and angiogenesis in various physiological as well as pathological settings. The concentration of VEGF is a critical determinant of its biological effect as indicated by the haploinsufficiency of VEGF in mice (7, 8) , leading to impaired vascular development. In contrast, delivery of excess VEGF to the brain via viral agents (26, 27) or administration of VEGF protein (28, 29) induces large and thin-walled blood vessels. Thus, a number of investigators have pursued the idea that vascular malformations occur as a result of uncontrolled activation of the VEGF/VEGFR-system. Indeed, whereas VEGF and its receptors are normally downregulated in cerebral blood vessels after birth as angiogenesis ceases, increased expression of the VEGF/VEGFR system has been demonstrated in vascular malformations (23, 30Y32). We similarly observed increased EC-specific staining for VEGF as well as VEGFR-1, VEGFR-2, and the co-receptor NP-1 in LA lesions of SWS patients in conjunction with increased EC proliferation. ECs in SWS were positive for VEGF protein, but did not express VEGF mRNA. However, VEGF mRNA transcripts were found to be elevated in the bordering brain tissue suggesting that VEGF is secreted by neurons and glia in the underlying cortex and subsequently bound by SWS vessels. Therefore, VEGF could act in a paracrine fashion on the SWS vasculature expressing the corresponding receptors. Elevated VEGF levels could also explain the increased vascular permeability observed in cortical SWS lesions (33, 34) .
The high levels of VEGF in SWS specimens may be induced by cerebral hypoxia, an important regulator of VEGF expression, as vascular thrombosis and brain ischemia are associated with SWS disease (4, 5) . Cortical astrogliosis, a kind of cerebral scarring, could be considered as an indicator for chronic hypoxia and malnutrition of the cerebral cortex. Indeed, we observed twice the number of astrocytes in SWS samples as compared to control tissues. Interestingly, animal models of chronic brain hypoperfusion demonstrate that ischemic conditions induce engorgement and dilation of the pial vessels (35) , thus mimicking the SWS phenotype, suggesting that decreases in oxygen tension may be implicated in driving the disease process of LA.
As described for other vascular malformations (36), we detected increased mitotic activity in ECs of SWS vessels. We interpret this as evidence for ongoing angiogenesis. EC proliferation in SWS lesions exceeded the proliferation rates reported for the quiescent vasculature (37) approximately 25-fold (0.25% versus 0.01%). Moreover, single SWS vessels harbored apoptotic ECs, suggesting that the vasculature undergoes frequent remodeling. It is difficult to ascertain the relationship of proliferation to cell death in ECs of SWS patients. However, clinical evidence has documented the progressive nature of SWS lesions (38) possibly due to vascular proliferation, indicating that net EC proliferation exceeds EC apoptosis. We and others have previously reported that vascular remodeling is controlled by an exquisite crosstalk between the VEGF/VEGFR and the angiopoietin/Tie2 system during brain development (39), brain ischemia (24) , or arteriovenous malformations (40) . SWS vessels also demonstrated an increase in Tie2 expression, indicating a possible role of this molecular pathway in the observed remodeling events. In summary our data suggest that the VEGF/VEGFR and the angiopoietin/Tie2 system may be instrumental in the pathogenesis of abnormal SWS vessels.
Endothelial Cell-Specific HIF-> Expression
An unexpected finding was the constitutively high expression of HIF-1> and HIF-2> in ECs of leptomeningeal vessels. Recent studies suggest that HIF may operate as an intrinsic regulator of EC growth and function by stimulating receptor and ligand expression. HIF->/hypoxia transcriptionally control VEGFR-1, VEGFR-2, NP-1 and Tie2 expression (18Y21, 41). Moreover, stabilization of HIF-1> by the peptide regulator 39 in different EC lines increased VEGF expression and accelerated formation of vascular structures (42) . In contrast, conditional deletion of HIF-1> or expression of a dominant-negative HIF construct in ECs reduced EC proliferation, decreased tumor vascularization, and impaired vascular growth during embryonic development (43, 44) . Based on these findings, we hypothesize that the increased levels of the HIF target genes VEGFR-1, VEGFR-2, NP-1, and Tie2 in LA may be the consequence of the HIF upregulation in SWS vessels. In this context, it is interesting to note that SWS lesions have been proposed to be remnants of the primitive embryonic vascular plexus due to impaired vessel regression (1). Primitive cerebral blood vessels express high levels of HIF-2> that are coordinately downregulated as the brain and vascular network matures, thus correlating with the declining angiogenic activity (21) . It is tempting to speculate that localized misregulation or failed downregulation of HIF activation could impair regression and maturation of the vascular plexus. Hence, cell-autonomous endothelial HIF activation may contribute to or even determine the angiogenic EC phenotype in SWS lesions.
ECs of intracortical blood vessels in SWS patients did not demonstrate increased HIF-> levels suggesting alterations in HIF regulation that are specific to ECs of SWS vascular malformations. What mechanisms could increase HIF-> levels? The exposure of ECs to intermittent or chronic hypoxic conditions as a result of the structural and functional abnormal tumor vasculature is well documented (45) . Correspondingly, heterogeneous perfusion of SWS vessels could lead to reduced oxygenation of SWS lesions. However, we could not detect increased HIF expression in subendothelial cell layers, which should encounter equally low oxygen levels, as has been reported for thrombosed vascular malformations (46) . Thus, our results suggest that other factors besides PO 2 underlie the observed EC-specific upregulation of HIF-1> and HIF-2> in leptomeningeal vessels. Two major intracellular signal transduction pathways, namely the PI3K-AKT-FRAP and the RAS-RAF-MEK-ERK pathway, have been found to enhance HIF activity (47) . It is tempting to speculate that the increased VEGF levels in SWS lesions could by stimulating VEGFR-2 signaling likewise upregulate HIF->, in turn leading to transactivation of VEGFR-2 and further activation of this pathway. Our results indicate that VEGF treatment of EC increases HIF-> levels (data not shown). A similar autocrine growth factor receptor loop has been demonstrated for insulin like growth factor (IGF)-2/IGF-R1 and HIF-1> (48), underlining the possible central role of VEGF in SWS lesions.
Apart from activation by hypoxia and various growth factor pathways, HIF-> expression is increased in response to genetic alterations. In this context, it is interesting to note that a genetic susceptibility to SWS or somatic mutations have long been suspected, but not yet detected. Heterozygous mutations affecting succinate dehydrogenase and fumarate hydratase are associated with hereditary predispositions to various highly vascularized tumors (49, 50) . Both succinate and fumarate, metabolites of these enzymes, have been shown to increase HIF-1> protein levels by PHD inhibition (51, 52) . VHL loss of function frequently found in hemangioblastomas and renal cell carcinomas similarly stabilizes HIF-> subunits by impairing HIF degradation. Embryos with EC-specific ablation of VHL exhibit dilated vessels due to decreased fibronectin deposition (53) . Intriguingly, decreased fibronectin expression has previously been reported in vessels of LA (54) . Thus, further studies are necessary to determine to what degree HIF regulating mechanisms affecting, for example PHD or VHL function may be impaired in SWS disease.
Propagation of SWS Disease
So far, only a handful of studies have tried to analyze the molecular mechanisms determining SWS-specific vascular malformations. Our results support and extend previous observations of dysregulated vessel homeostasis in SWS and indicate that vascular lesions in SWS are angiogenic and progressive in nature. Several studies have proposed a general concept of how vascular malformations contribute to the generation of a pro-angiogenic microenvironment that helps to sustain and propagate the nidus of the lesion (31) . We would like to propose, by analogy to a recent review (1), a similar model for SWS with VEGF as a central angiogenic regulator. In this model, EC extrinsic and intrinsic angiogenic pathways would contribute to the maintenance and propagation of vascular malformations in SWS (Fig. 5) . Thus, in terms of angiogenesis, LA of SWS are not static lesions but sites of active vascular remodeling dynamically interacting with the underlying brain. The progressive symptoms of SWS may occur as the result of local changes in lesion size due to secondary vascular proliferation. In future studies it will be important to determine whether angiogenesis is essential for the propagation of the disease process and, hence, whether SWS lesions might be amenable to anti-angiogenic therapy with FIGURE 5 . Hypothetical model on the role of HIF-1> and HIF-2> in Sturge-Weber syndrome (SWS) disease. In this model endothelial cell (EC) extrinsic and intrinsic angiogenic pathways contribute to the maintenance and propagation of vascular malformations in SWS. We hypothesize that venous stasis or inhomogeneous blood flow in the leptomeningeal malformation would impair cortical perfusion resulting in ischemic injury to the cortical tissue. Decreased cortical oxygen tension elevates VEGF levels in the cortex underlying the lesion (EC extrinsic pathway). Whether pathophysiological or genetic in cause the increased endothelial HIF expression (EC intrinsic pathway) renders EC highly sensitive to these local increases in VEGF levels by inducing the expression of VEGFR-1, VEGFR-2 and its co-receptor NP-1 concomitantly with Tie2 triggering an enhanced angiogenic response. As a result SWS lesions extend and progress.
anti-VEGF neutralizing antibodies or HIF destabilizing agents that are currently in clinical trials.
